These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30615532)

  • 1. The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs.
    Hernandez I; Good CB; Cutler DM; Gellad WF; Parekh N; Shrank WH
    Health Aff (Millwood); 2019 Jan; 38(1):76-83. PubMed ID: 30615532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition.
    Zhang JX
    PLoS One; 2020; 15(6):e0234463. PubMed ID: 32525965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.
    Guan X; Tian Y; Ross-Degnan D; Man C; Shi L
    BMJ Open; 2018 Jul; 8(7):e022328. PubMed ID: 30012792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brand-name versus generic.
    Copeland KR; Boccuzzi SJ
    Health Aff (Millwood); 2007; 26(4):1198-9; author reply 1199. PubMed ID: 17630468
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.
    Danzon PM; Mulcahy AW; Towse AK
    Health Econ; 2015 Feb; 24(2):238-52. PubMed ID: 24293058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Evolution of Supply and Demand in Markets for Generic Drugs.
    Frank RG; McGuire TG; Nason I
    Milbank Q; 2021 Sep; 99(3):828-852. PubMed ID: 34075623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
    Cheng N; Banerjee T; Qian J; Hansen RA
    J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies That Delay Market Entry of Generic Drugs.
    Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
    JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reference pricing with endogenous generic entry.
    Brekke KR; Canta C; Straume OR
    J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do higher-priced generic medicines enjoy a competitive advantage under reference pricing?
    Puig-Junoy J
    Appl Health Econ Health Policy; 2012 Nov; 10(6):441-51. PubMed ID: 22900924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperinflation: Definitions and Causes.
    Saltiel M; Finnefrock M
    J Pharm Pract; 2020 Apr; 33(2):183-186. PubMed ID: 30099947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who's really raising drug prices?
    Zagorin A
    Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
    [No Abstract]   [Full Text] [Related]  

  • 19. Price competition in pharmaceuticals - Evidence from 1303 Swedish markets.
    Granlund D; Bergman MA
    J Health Econ; 2018 Sep; 61():1-12. PubMed ID: 30007260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
    Dickson S
    JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.